Cellular homeostatic tension and force transmission measured in human engineered tendon by Giannopoulos, Antonis et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Cellular homeostatic tension and force transmission measured in human engineered
tendon
Giannopoulos, Antonis; Svensson, Rene B.; Heinemeier, Katja M; Schjerling, Peter; Kadler,
Karl E; Holmes, David F; Kjær, Michael; Magnusson, S. Peter
Published in:
Journal of Biomechanics
DOI:
10.1016/j.jbiomech.2018.07.032
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Giannopoulos, A., Svensson, R. B., Heinemeier, K. M., Schjerling, P., Kadler, K. E., Holmes, D. F., ...
Magnusson, S. P. (2018). Cellular homeostatic tension and force transmission measured in human engineered
tendon. Journal of Biomechanics, 78, 161-165. https://doi.org/10.1016/j.jbiomech.2018.07.032
Download date: 03. Feb. 2020
Journal of Biomechanics 78 (2018) 161–165Contents lists available at ScienceDirect
Journal of Biomechanics
journal homepage: www.elsevier .com/locate / jb iomech
www.JBiomech.comShort communicationCellular homeostatic tension and force transmission measured in human
engineered tendonhttps://doi.org/10.1016/j.jbiomech.2018.07.032
0021-9290/ 2018 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author at: Institute of Sports Medicine Copenhagen, Bispebjerg-
Frederiksberg Hospital, Bldg. 8, Nielsine Nielsens Vej 11, DK-2400 Copenhagen, NV,
Denmark.
E-mail address: p.magnusson@sund.ku.dk (S.P. Magnusson).Antonis Giannopoulos a, Rene B. Svensson a, Katja M. Heinemeier a, Peter Schjerling a, Karl E. Kadler c,
David F. Holmes c, Michael Kjaer a, S. Peter Magnusson a,b,⇑
a Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Bispebjerg-Frederiksberg Hospital and Center for Healthy Aging, Faculty of Health Sciences, University
of Copenhagen, Denmark
bDepartment of Physical and Occupational Therapy, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark
cWellcome Trust Centre for Cell-Matrix Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester
M13 9PT, UK
a r t i c l e i n f oArticle history:
Accepted 20 July 2018
Keywords:
Cell-matrix interaction
Fibroblast
Force monitor
Mechanics
Tissue engineeringa b s t r a c t
Tendons transmit contractile muscular force to bone to produce movement, and it is believed cells can
generate endogenous forces on the extracellular matrix to maintain tissue homeostasis. However, little
is known about the direct mechanical measurement of cell-matrix interaction in cell-generated human
tendon constructs. In this study we examined if cell-generated force could be detected and quantified
in engineered human tendon constructs, and if glycosaminoglycans (GAGs) contribute to tendon force
transmission. Following de-tensioning of the tendon constructs it was possible to quantify an endoge-
nous re-tensioning. Further, it was demonstrated that the endogenous re-tensioning response was mark-
edly blunted after interference with the cytoskeleton (inhibiting non-muscle myosin-dependent cell
contraction by blebbistatin), which confirmed that re-tensioning was cell generated. When the constructs
were elongated and held at a constant length a stress relaxation response was quantified, and removing
27% of the GAG content of tendon did not alter the relaxation behavior, which indicates that GAGs do not
play a meaningful role in force transmission within this system.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The chief function of tendon is to transmit contractile muscular
force to bone to produce movement. It has been shown that placing
sizeable repetitive loads on the tendon may influence numerous
cell responses (Spiesz et al., 2015), tissue composition (Langberg
et al., 1999) and mechanical properties of the tendon (Hansen
et al., 2003), which indicates that tendon tissue is mechanorespon-
sive although the precise pathway is unknown (Harris et al., 1980;
Wang et al., 2012). This conversion of a mechanical stimulus into
an electrochemical action and intracellular biochemical response
demonstrate that tendons are capable of mechanotransduction.
While the tendon can impart forces on the cell, it is also possible
for cell to generate endogenous forces on the extracellular matrix
(ECM) (Eastwood et al., 1994; Kolodney and Wysolmerski, 1992),
which allows for a fine-tuned dynamic interaction between the celland the ECM to maintain tissue homeostasis (Freedman et al.,
2015; Joshi et al., 1985).
The ability for cells to exert forces on the ECM has previously
typically been quantified using a polymeric collagen lattice to
show that cells can control homeostatic tension when measured
over hours to days (Delvoye et al., 1991; Eastwood et al., 1994).
Sponge gels with defined properties have also been used as scaf-
folds to evaluate cell responses (Brown et al., 1998; Delvoye
et al., 1991; Kolodney and Wysolmerski, 1992). However, cell-
generated scaffolds comprise a mixture of ECM components that
more likely resemble that of the in vivo situation compared to
the aforementioned models. Such cell-derived tendon construct
have therefore been developed using both animal (Kapacee et al.,
2008) and human cells (Bayer et al., 2010), with similar composi-
tion (Kapacee et al., 2008) and mechanical properties
(Herchenhan et al., 2013) to embryonic tendon tissue (Kalson
et al., 2010). Tension appears critical for the formation and devel-
opment of these constructs, which underscores the importance of
mechanotransduction (Bayer et al., 2014; Kapacee et al., 2008).
However, direct mechanical measurement of cell-matrix interac-
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reported before.
The principle force transmitting structure of the ECM in mature
tendon tissue is the fibril (Cribb and Scott, 1995; Parry et al., 1978).
It has been suggested that force is transferred between adjacent
fibrils via proteoglycans and their associated glycosaminoglycan
(GAG) chains, including chondroitin- and dermatan-sulfate (Ryan
et al., 2015; Scott and Thomlinson, 1998). However, removing this
complex in tendon (Svensson et al., 2011) and ligament
(Provenzano and Vanderby, 2006) does not appreciably affect the
mechanical properties of the tissue. Moreover, it was recently
shown that fibrils appear to be continuous in mature tendon tissue,
suggesting that the importance of lateral force transmission
between fibrils may be negligible (Svensson et al., 2017). However,
in the early stages of developing tendon tissue the fibrils are dis-
continuous (Birk et al., 1995), and the relative amount of non fib-
rillar matrix is larger. Therefore it is possible that a mechanism
for lateral force transmission is necessary, but this has never been
investigated. Hence, the purpose of this study was two-fold; (1) to
examine if cell generated force could be detected and quantified in
engineered human tendon constructs, and (2) to assess if GAGs
contribute to transmission of force in this human cell generated
tendon tissue.2. Materials and methods
2.1. Tendon construct preparation
Cells were obtained as previously described (Bayer et al., 2010)
(see supplement for details). In brief, tendon fibroblasts were iso-
lated from semitendinosus and gracilis tendon from patients that
underwent reconstructive anterior cruciate ligament (ACL) sur-
gery. All the cell lines from different donors were obtained from
the same source. Informed consent was obtained from all tissue
donors in accordance with ethical approval [H-3-2010-070]. Cells
were isolated using collagenase type II and seeded into culture
flasks (DMEM/F12, 10% FPB). Cells between passages 2 and 6 were
used for experiments.
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.jbiomech.2018.07.
032.
Tendon constructs from human tendon fibroblasts were made
as previously described (Bayer et al., 2010) (see supplement for
details). Briefly, each well of a six well plate was coated with Syl-
gard (DoW Chemicals). Two loop shaped silk sutures were pinned
10 mm apart to the coated plates and sterilized in 70% ethanol.
Fibroblasts were suspended in a mix of fibrinogen, aprotinin and
thrombin (all from Sigma Aldrich) to a final concentration of 0.2
million cells per well. The 3D gels were incubated in construct
medium (DMEM/F12, 10% FBS, 0.2 mM L-ascorbic acid
2-phosphate, 0.05 mM L-proline), which was replaced every other
day. Approximately 2 weeks after seeding the constructs were fully
formed (the matrix contracted to a 10 mm long narrow linear
structure between the sutures).2.2. Mechanical evaluation
A custom made system was used to measure forces in cell
derived human tendon constructs. Briefly, the system consisted
of force transducers (402A, Aurora Scientific, CA), stepper motors
with a motor controller (Astrosyn, Y129-5, PC-control ltd., UK), cul-
ture wells and a PC data collection system (Microlink 751, Biodata
ltd., UK). Strain was applied by the stepper motors via a threaded
rod with a step resolution of 2.25 µm. Deformation was applied
at a rate of 56 µm/s and force data sampled at 1 Hz. Constructswere attached by their silk suture loops to the motor and force
transducer via stainless steel hooks (Fig. 1A).
2.3. Mechanical testing protocol
Mechanical tests were performed in an incubator (37 C and 5%
CO2). The Sylgaard coating underneath the construct was cut into a
strip and transferred together with the pinned construct to the
force monitoring system to avoid altering the original length and
tension. Thereafter, the constructs were relaxed by 0.225 mm to
confirm the presence of tension. If tension was present the length
was returned to the original position. If there was no tension the
constructs were considered to have become slightly slack during
transfer and were stretched in 0.225 mm steps up to 0.675 mm
to re-establish tension. This position was defined as the baseline
length and subsequently the system was allowed to stabilize for
1 h. The tendon constructs were subjected to a protocol that con-
sisted of three cycles, with each cycle consisting of 0.675 mm of
unloading (reducing length), 300 s of rest period followed by
0.675 mm of reloading (returning to the initial length) and another
300 s of rest (see Fig. 1B).
2.4. Construct treatment
Tendon constructs were tested at either 3, 4 or 5 weeks after
seeding (based on 5 cell lines). The tendon constructs underwent
three cyclic stretches in normal medium (DMEM). Immediately
after, the normal medium was replaced with treatment media
(DMEM plus reagent) followed by an incubation period of 30 min
and three subsequent cycles. Blebbistatin (B0560, SIGMA)
(17 µM) was used for inhibiting non-muscle myosin-dependent
cell contraction (n = 24: week 3, n = 8, week 4, n = 7, week 5, n =
9), and chondroitinase ABC (C3667, SIGMA) (0.07U/ml) was used
to digest glycosaminoglycans (n = 23: week 3, n = 8, week 4, n =
7, week 5, n = 8). Control samples (n = 10 from 2 cell lines: week
3, n = 4, week 5, n = 6) that had normal medium replaced with
fresh normal medium were also mechanically tested in the same
manner to control for the effect of time (untreated controls).
2.5. Glycosaminoglycan determination
Sulfated GAG content was determined in the mechanically
tested constructs using a 1,9-dimethylmethylene blue (DMMB)
assay slightly modified from (Hoemann, 2004) and was expressed
as µg per construct (see details in supplement).
2.6. Statistics and data reduction
The force values were determined at four different points in
each cycle (see Fig. 1B): A) at the end of relaxation (300 s). B)
Immediately following unloading. C) At the end of re-tension
(300 s). D) Immediately following reloading. Average values of
the 3 cycles were used for each sample before and after treatment.
Re-tension was calculated as: (C  B)/(A  B), which corresponds
to the relative amount of re-tension. Stress relaxation was calcu-
lated as: (D  A)/(D  C), which also corresponds to the relative
amount of relaxation. Re-tension and relaxation are expressed as
a percentage and the treatment effect is the absolute difference
between the pre and post percentage values.
The effect of treatment and construct maturity on mechanical
behavior was examined with 2-way ANOVA’s with post hoc Sidak’s
multiple comparison tests (GraphPad Software, La Jolla California
USA). Unpaired t-tests were used to compare GAG content and
change in re-tension between chondroitinase and blebbistatin
treated constructs and to compare the baseline mechanics (before
treatment) between week 3 and 5. The primary comparison was
AFig. 1. Mechanical test system. (A) The force monitor system which consists of two stepper motors, culture wells and force transducers. (B) Example of force vs. time data for
one cycle measurement. At point ‘A’ the construct is unloaded to point ‘B’ where the force is allowed to re-tension for 300 s. At point ‘C’ the construct is stretched back to its
initial position (point ‘D’) with the length remaining constant for 300 s, relaxing back to point ‘A’ where another cycle starts.
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additional control, unpaired t-tests were also made against the
untreated controls. Results are reported as mean ± SE.B
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In untreated controls re-tension decreased over time (3.5 ± 1.
2%, n = 10, p < 0.05) but relaxation was unaffected (0.8 ± 0.5%,
n = 10, p = 0.14) indicating little effect of time. Blebbistatin treat-
ment significantly reduced re-tension compared to pre-treatment
(Fig. 2A, p < 0.005, main effect) but had no effect on relaxation
(Fig. 2B, p = 0.97, main effect). Blebbistatin treatment did not affect
GAG content (7.17 ± 0.35 µg, n = 29) compared to the untreated
controls (6.84 ± 0.63 µg, n = 7). Chondroitinase treatment reduced
the total GAG content of the tendon constructs (5.24 ± 0.22 µg,
n = 27) by 27% compared to blebbistatin treated constructs (p < 0.
0001). Chondroitinase did not affect re-tension (Fig. 3A, p = 0.87,
main effect) or relaxation (p = 0.74, main effect) of the constructs
(Fig. 3).
The change in re-tension with blebbistatin (-10.6 ± 1.6%, n = 24)
was significantly different from the change with chondroitinase
treatment (0.8 ± 1.5%, n = 23, p < 0.0001) and from the change
in untreated controls (p < 0.05). While the effect of treatment did
not differ between weeks there was a baseline reduction in re-
tension from week 3 (29.4 ± 3.6%, n = 16) to 5 (18.0 ± 3.4%, n = 17,
p = 0.029). There was no significant baseline difference in relax-
ation from week 3 (66.9 ± 2.8%, n = 16) to 5 (62.8 ± 2.4%, n = 17,
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Fig. 2. Blebbistatin treatment for cell contraction inhibition. (A) The re-tension
dropped significantly after blebbistatin treatment (p < 0.005). B) The relaxation
phase was unaffected by cell contraction inhibition. (n = 24 from 5 cell lines: week
3, n = 8, week 4, n = 7, week 5, n = 9).4. Discussion
In the present study we sought to examine if cell-generated
force could be detected and quantified in engineered human ten-
don constructs. When the constructs were unloaded an endoge-
nous force was generated that could be quantified (see Fig. 1A),
and following inhibition of cell contractility by blebbistatin (an
inhibitor of non-muscle myosin) (Cai et al., 2006; Even-Ram
et al., 2007; Kalson et al., 2013), the re-tension was dramatically
reduced, which indicates that the endogenous force is cell-
generated. Complete loss of re-tension did not occur, which may
relate to the short treatment time.
The fact that the cells have the ability to generate internal tissue
tension and thereby maintain homeostasis is well known and has
been studied in different models. However, to the best of our
knowledge, this is the first report of cell-generated tissue tension
in a 3D human tendon scaffold. The advantage of this model is thatthe cells produce and organize their own collagen matrix
(Herchenhan et al., 2013; Kalson et al., 2010).
The magnitude of re-tensioning was less in week 5 compared to
week 3 constructs. This could be the result of a lower cell number,
but an assessment of nuclei area fraction did not reveal a difference
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Fig. 3. Chondroitinase ABC (CH ABC) treatment for glycosaminoglycan digestion.
(A) The re-tension did not change after CH ABC treatment. (B) The relaxation also
remain unaffected after the treatment. (n = 23 from 5 cell lines: week 3, n = 8, week
4, n = 7, week 5, n = 8).
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shown that cell number declines over time in similar constructs
(Delvoye et al., 1991; Kalson et al., 2010). On the other hand, it
has been shown that the stiffness of the construct increases dra-
matically from week 2 to 5 (Herchenhan et al., 2013), and it is pos-
sible that the increased collagen stiffness itself reduces the
magnitude of the cell contraction (Karamichos et al., 2007). The
relative contribution of a potential decline in cell number or aug-
mented construct properties cannot be ascertained in the present
study.
While the unloading allowed for an evaluation of the cell-
generated response, the relaxation phase represents the response
of the extracellular component of the matrix. As mentioned earlier,
GAGs could influence force transmission in the immature con-
structs. However, in the present study we show that a 27% reduc-
tion of GAG content did not impact the relaxation phase of the 3–5
week constructs, which implies that this is not a critical force
transmission pathway in these tissues.
In conclusion, these data show the presence of cell-generated
tension within the human tendon constructs. This observation
was supported by a 38% decline in cell re-tension after introducing
a cell contraction inhibitor. In addition, a 27% reduction in GAGcontent did not seem to affect force transmission in this system.
The ability of our system to apply, detect and quantify the gener-
ated forces in real time provides new insight to the field of tendon
biomechanics. The force monitor is a useful tool to investigate tis-
sue development and regeneration by evaluating cell-matrix
interactions.
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